In total, 15.9% of HFpEF patients were treated with angiotensin receptor/neprilysin inhibitor (ARNI) because of a previous history of HF with ejection fraction <40% that improved their ventricular function and, of course, maintained the optimized therapy. This evidence concerns the gene MME and hydrops fetalis.